To the content
3 . 2022

Effect of cholecalciferol supplementation on the clinical course of hospitalized COVID 19 patients

Abstract

The aim of this study was to evaluate the effect of cholecalciferol supplementation on the clinical course of hospitalized patients with moderate-to-severe COVID‑19. Results showed the baseline prevalence of a low 25-hydroxyvitamin D level. We demonstrated that 100 000 IU cholecalciferol supplementation in addition to the standard therapy is associated with a 25-hydroxyvitamin D level increase (average of 40.7%) as well as with the significantly higher levels of lymphocytes and neutrophils at the 9th day of hospitalization (p=0.047; p=0,025). Thus, vitamin D supplementation can be considered as an adjunctive treatment for COVID‑19.

Keywords:COVID 19; SARS-CoV 2; vitamin D; 25(OH)D; cholecalciferol

Funding. This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2022-301).

Conflict of interest. The authors declare no conflict of interest.

For citation: Mikhailova A.A., Lagutina D.I., Golovatyuk K.А. Effect of cholecalciferol supplementation on the clinical course of hospitalized COVID‑19 patients. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (3): 119–21. DOI: https://doi.org/10.33029/2304-9529-2022-11-3-119-121 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»